Last deal

$5.5M
Local Amount - EUR 5.M

Amount

Series A

Stage

14.08.2023

Date

1

all rounds

$5.5M

Total amount

General

About Company
VRG Therapeutics develops miniprotein-based meds and gene therapy to cure untreatable diseases.

Industry

Sector :

Subsector :

Also Known As

VRG Tx, Vascular Research Group

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

The company's unique platform utilizes directed evolution to optimize peptides and proteins of natural origin, creating cutting-edge products in the form of miniprotein-based medications and peptide-based pharmaceuticals. VRG Therapeutics has a team of highly experienced professionals with expertise in preclinical and clinical research and development, scientific project management, pharmacology, business development, and medical marketing. The team members have worked in renowned academic institutes and leading pharmaceutical companies, bringing their international research experience and outstanding achievements in the pharma industry to VRG Therapeutics.
Contacts